BeOne Medicines Ltd.

NASDAQ

Market Cap.

26.79B

Avg. Volume

446.26K

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about BeOne Medicines Ltd.

BeOne Medicines Ltd. News

BeOne Medicines Ltd. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock
Website screenshot
HealthcareMedical - Pharmaceuticals
beonemedicines.com

About BeOne Medicines Ltd.

BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.

BeOne Medicines Ltd. Earnings & Revenue

What’s This Company Really Worth? Find Out Instantly.

Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.

BeOne Medicines Ltd. Financials

Table Compare

Compare ONC metrics with:

   

Earnings & Growth

ONC

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

ONC

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

ONC

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

ONC

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

BeOne Medicines Ltd. Income

BeOne Medicines Ltd. Balance Sheet

BeOne Medicines Ltd. Cash Flow

BeOne Medicines Ltd. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Sell
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioSell
Price/Earnings RatioStrong Sell
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

BeOne Medicines Ltd. Executives

NameRole
Dr. Xiaodong Wang Ph.D.Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder
Mr. John V. OylerCo-Founder, Executive Chairman & Chief Executive Officer
Mr. Aaron RosenbergChief Financial Officer
Dr. Xiaobin Wu Ph.D.President, Chief Operating Officer & GM of China
Mr. Wang Lai Ph.D.Global Head of R&D
NameRoleGenderDate of BirthPay
Dr. Xiaodong Wang Ph.D.Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder19634.25M
Mr. John V. OylerCo-Founder, Executive Chairman & Chief Executive OfficerMale19682.84M
Mr. Aaron RosenbergChief Financial OfficerMale19771.93M
Dr. Xiaobin Wu Ph.D.President, Chief Operating Officer & GM of China19631.84M
Mr. Wang Lai Ph.D.Global Head of R&DMale19781.2M

BeOne Medicines Ltd. Insider Trades

Date10 Jun
NameBall Titus B.
RolePrincipal Accounting Officer
TransactionAcquired
TypeA-Award
Shares29601
Date11 Jun
NameBall Titus B.
RolePrincipal Accounting Officer
TransactionDisposed
TypeS-Sale
Shares134
Date10 Jun
NameLee Chan Henry
RoleSVP, General Counsel
TransactionAcquired
TypeA-Award
Shares46878
Date10 Jun
NameLee Chan Henry
RoleSVP, General Counsel
TransactionAcquired
TypeA-Award
Shares88244
Date10 Jun
NameRosenberg Aaron
RoleChief Financial Officer
TransactionAcquired
TypeA-Award
Shares63674
DateNameRoleTransactionTypeShares
10 JunBall Titus B.Principal Accounting OfficerAcquiredA-Award29601
11 JunBall Titus B.Principal Accounting OfficerDisposedS-Sale134
10 JunLee Chan HenrySVP, General CounselAcquiredA-Award46878
10 JunLee Chan HenrySVP, General CounselAcquiredA-Award88244
10 JunRosenberg AaronChief Financial OfficerAcquiredA-Award63674

Discover More

Streamlined Academy

BeOne Medicines Ltd.

NASDAQ

Market Cap.

26.79B

Avg. Volume

446.26K

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

BeOne Medicines Ltd. News

BeOne Medicines Ltd. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock

BeOne Medicines Ltd. Earnings & Revenue

BeOne Medicines Ltd. Income

BeOne Medicines Ltd. Balance Sheet

BeOne Medicines Ltd. Cash Flow

BeOne Medicines Ltd. Financials Over Time

BeOne Medicines Ltd. Executives

NameRole
Dr. Xiaodong Wang Ph.D.Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder
Mr. John V. OylerCo-Founder, Executive Chairman & Chief Executive Officer
Mr. Aaron RosenbergChief Financial Officer
Dr. Xiaobin Wu Ph.D.President, Chief Operating Officer & GM of China
Mr. Wang Lai Ph.D.Global Head of R&D
NameRoleGenderDate of BirthPay
Dr. Xiaodong Wang Ph.D.Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder19634.25M
Mr. John V. OylerCo-Founder, Executive Chairman & Chief Executive OfficerMale19682.84M
Mr. Aaron RosenbergChief Financial OfficerMale19771.93M
Dr. Xiaobin Wu Ph.D.President, Chief Operating Officer & GM of China19631.84M
Mr. Wang Lai Ph.D.Global Head of R&DMale19781.2M

BeOne Medicines Ltd. Insider Trades

Date10 Jun
NameBall Titus B.
RolePrincipal Accounting Officer
TransactionAcquired
TypeA-Award
Shares29601
Date11 Jun
NameBall Titus B.
RolePrincipal Accounting Officer
TransactionDisposed
TypeS-Sale
Shares134
Date10 Jun
NameLee Chan Henry
RoleSVP, General Counsel
TransactionAcquired
TypeA-Award
Shares46878
Date10 Jun
NameLee Chan Henry
RoleSVP, General Counsel
TransactionAcquired
TypeA-Award
Shares88244
Date10 Jun
NameRosenberg Aaron
RoleChief Financial Officer
TransactionAcquired
TypeA-Award
Shares63674
DateNameRoleTransactionTypeShares
10 JunBall Titus B.Principal Accounting OfficerAcquiredA-Award29601
11 JunBall Titus B.Principal Accounting OfficerDisposedS-Sale134
10 JunLee Chan HenrySVP, General CounselAcquiredA-Award46878
10 JunLee Chan HenrySVP, General CounselAcquiredA-Award88244
10 JunRosenberg AaronChief Financial OfficerAcquiredA-Award63674

Streamlined Academy

Website screenshot
HealthcareMedical - Pharmaceuticals
beonemedicines.com

About BeOne Medicines Ltd.

BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about BeOne Medicines Ltd.

What’s This Company Really Worth? Find Out Instantly.

Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.

BeOne Medicines Ltd. Financials

Table Compare

Compare ONC metrics with:

   

Earnings & Growth

ONC

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

ONC

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

ONC

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

ONC

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Sell
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioSell
Price/Earnings RatioStrong Sell
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More

The Secret to Analyzing Winning Stocks (Step-by-Step Examples Inside)